+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
AJANTPHARM

Ajanta Pharma Share Price

₹3,284.00 -40 (-1.2%)
34.27% Gain from 52W Low

13 Nov, 2026 3:54 PM (IST)

Ajanta Pharma live price: ₹3,284.00. It opened at ₹3,340 vs previous close ₹3,324; intraday high/low: ₹3,342/₹3,265. The 50 & 200 DMA stand at ₹3,401.80/₹3,221.60.

Ajanta Pharma Performance

  • Today's Low
  • ₹3,265
  • Today's High
  • ₹3,342
  • 52 Week Low
  • ₹2,446
  • 52 Week High
  • ₹3,796
  • Open Price₹3,340
  • Previous Close₹3,324
  • Volume198,757
  • 50 DMA₹3,401.80
  • 100 DMA₹3,368.20
  • 200 DMA₹3,221.60

Ajanta Pharma Chart

Investment Returns

  • Over 1 Month -0.45%
  • Over 3 Month -10.59%
  • Over 6 Month + 0.76%
  • Over 1 Year + 30.15%

Smart Investing Starts Here Start SIP with Ajanta Pharma for Steady Growth!

Invest Now

Ajanta Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 32.5
  • PEG Ratio
  • 1.1
  • Market Cap Cr
  • 41,037
  • P/B Ratio
  • 8.4
  • Average True Range
  • 103.8
  • EPS
  • 101.1
  • Dividend Yield
  • 1
  • MACD Signal
  • -34.8
  • RSI
  • 41.03
  • MFI
  • 48.88

Latest Stock News Updates

Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 09, 2026 for Aayush Agrawal, trustee Aayush Agrawal Trust

Ajanta Pharma Ltd - 532331 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Pls find enclosed Earnings Call Written Transcript

Ajanta Pharma Ltd - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Pls find enclosed newspaper publication of financial results for the quarter ended 30.09.2026.

Ajanta Pharma Financials

Ajanta Pharma Technicals

EMA & SMA

Current Price
₹3,284.00
-40 (-1.2%)
pointer
  • Bearish Moving Average 14
  • Bullish Moving Average 2
  • 20 Day
  • ₹3,353.90
  • 50 Day
  • ₹3,401.80
  • 100 Day
  • ₹3,368.20
  • 200 Day
  • ₹3,221.60

Resistance and Support

3297.1 Pivot Speed
  • R3 3,406.50
  • R2 3,374.40
  • R1 3,329.20
  • S1 3,251.90
  • S2 3,219.80
  • S3 3,174.60

Ajanta Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-10-30 Quarterly Results
2026-07-30 Quarterly Results & Interim Dividend
2026-05-05 Audited Results
2026-01-30 Quarterly Results
2025-11-03 Quarterly Results & Interim Dividend
Date Purpose Remarks
2026-08-05 INTERIM Rs.32.00 per share(1600%)First Interim Dividend
2025-11-10 INTERIM Rs.28.00 per share(1400%)First Interim Dividend
2024-11-06 INTERIM Rs.28.00 per share(1400%)First Interim Dividend
2024-02-08 INTERIM Rs.26.00 per share(1300%)Second Interim Dividend
2023-08-04 INTERIM Rs.10.00 per share(500%)First Interim Dividend
View Ajanta Pharma Dividend History Arrow
Date Purpose Remarks
2012-08-10 Split
Date Purpose Remarks
2022-06-23 Bonus Bonus issue in the ratio of 1:2 of Rs. 2/-.

Ajanta Pharma Shareholding Pattern

63.47%
17.95%
7.62%
6.96%
3.99%

About Ajanta Pharma

Ajanta Pharma is primarily involved in development manufacturing and marketing of speciality pharmaceutical finished dosages.(Source : AR-PDF:202603-01 Pg No:109) View More
  • NSE Symbol
  • AJANTPHARM
  • BSE Symbol
  • 532331
  • ISIN
  • INE031B01049

Similar Stocks to Ajanta Pharma

Ajanta Pharma FAQs

Ajanta Pharma share price is ₹3,284 As on 15 November, 2026 | 22:08

The Market Cap of Ajanta Pharma is ₹41036.5 Cr As on 15 November, 2026 | 22:08

The P/E ratio of Ajanta Pharma is 32.5 As on 15 November, 2026 | 22:08

The PB ratio of Ajanta Pharma is 8.4 As on 15 November, 2026 | 22:08

The 52 week High & Low of Ajanta Pharma is ₹3796/₹2445.8 respectively As on 15 November, 2026 | 22:08

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23